Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Abstract Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurrent accumulation of disability. Over the past three...

Full description

Bibliographic Details
Published in:	Neurology and Therapy
Main Authors:	Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T. Reder
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-01-01
Subjects:	Disease-modifying therapies Interferons Interferon-beta-1a Interferon-β-1a for subcutaneous injection Multiple sclerosis Relapsing–remitting multiple sclerosis
Online Access:	https://doi.org/10.1007/s40120-023-00565-7

Similar Items

Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)
by: Pedersen ED, et al.
Published: (2018-04-01)

Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis
by: F. A. Khabirov, et al.
Published: (2024-08-01)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
by: Masoud Etemadifar, et al.
Published: (2011-01-01)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
by: Anthony Traboulsee, et al.
Published: (2018-09-01)

Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing–remitting multiple sclerosis treated with interferon beta-1a
by: Shlomo Flechter, et al.
Published: (2011-06-01)

Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study
by: Raed Al-Roughani, et al.
Published: (2023-11-01)

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
by: Mohammad Reza Gheini, et al.
Published: (2019-11-01)

Relevance of first-line drugs for treatment of multiple sclerosis in present-day conditions
by: N. Yu. Lashch
Published: (2020-12-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing–Remitting Multiple Sclerosis
by: Foziah Jabbar Gossab Alshamrani, et al.
Published: (2024-10-01)

Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients with Multiple Sclerosis
by: Ali Hekmatnia, et al.
Published: (2016-06-01)

REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program
by: Matthias Schwab, et al.
Published: (2024-03-01)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis
by: Edo Solsona MD, et al.
Published: (2017-03-01)

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study
by: Arpit Agrawal, et al.
Published: (2023-08-01)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
by: Chiara Zecca, et al.
Published: (2017-09-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Association of Multiple Sclerosis and Uveitis
by: Cansu Söylemez, et al.
Published: (2018-03-01)

Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1
by: Brandon C. Smith, et al.
Published: (2023-10-01)

Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis
by: Lin YT, et al.
Published: (2023-08-01)

Increased Circulating Levels of Vitamin D Binding Protein in MS Patients
by: Arturo Ottavio Rinaldi, et al.
Published: (2015-01-01)

اثرات درمانی افزودن ویتامین D به اینترفرون بتا a1 در بیماران مبتلا به Multiple sclerosis
by: Masoud Etemadifar, et al.
Published: (2016-02-01)

The evolution of interferon therapy in multiple sclerosis
by: O. V. Boyko, et al.
Published: (2023-08-01)

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority
by: Silvia Romano, et al.
Published: (2019-07-01)

Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis
by: Marco Aurélio Lana-Peixoto, et al.
Published: (2002-09-01)

Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report
by: Cristina-Florentina Plesa, et al.
Published: (2022-01-01)

Role of Diet and Supplementation with Omega-3 Polyunsaturated Fatty Acids for Managing Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis
by: Nicholas Shepherd, et al.
Published: (2022-11-01)

Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis
by: V. R. Mkrtchyan, et al.
Published: (2015-10-01)

Comparing the effects of swimming and running wheel on clinical symptoms and myelin basic protein in mice with experimental autoimmune encephalomyelitis
by: Maryam Karimian, et al.
Published: (2024-12-01)

Interferon Lambda Signaling Restrains Experimental Autoimmune Encephalomyelitis
by: Mohammad Asif Sherwani, et al.
Published: (2024-02-01)

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta
by: Pegah Sadat Fatehi, et al.
Published: (2018-11-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Recurrent Arthritis and Anti-cyclic Citrullinated Peptide Positivity during Interferon-beta 1a Treatment in Two Patients with Multiple Sclerosis
by: Hamed Cheraghmakani, et al.
Published: (2016-09-01)

Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial
by: Fereshteh Ashtari, et al.
Published: (2011-01-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
by: Hendin B, et al.
Published: (2018-07-01)

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
by: Elina Järvinen, et al.
Published: (2019-11-01)

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
by: L. M. Kuzenkova, et al.
Published: (2013-09-01)

Evaluation of interferon β-1b therapy effects on the level and abnormal nature of immunoglobulin G in patients with multiple sclerosis
by: K. M. Hychka, et al.
Published: (2018-12-01)

Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy
by: Mohammad Taheri, et al.
Published: (2017-02-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)